BRPI0815565A2 - Composições de esterol 24-c-metiltransferase de leishmania para a prevenção, tratamento e diagnóstico de leishmaniose. - Google Patents

Composições de esterol 24-c-metiltransferase de leishmania para a prevenção, tratamento e diagnóstico de leishmaniose.

Info

Publication number
BRPI0815565A2
BRPI0815565A2 BRPI0815565-8A2A BRPI0815565A BRPI0815565A2 BR PI0815565 A2 BRPI0815565 A2 BR PI0815565A2 BR PI0815565 A BRPI0815565 A BR PI0815565A BR PI0815565 A2 BRPI0815565 A2 BR PI0815565A2
Authority
BR
Brazil
Prior art keywords
leishmaniasis
methyltransferase
diagnosis
prevention
compositions
Prior art date
Application number
BRPI0815565-8A2A
Other languages
English (en)
Inventor
Steven Reed
Yasuyuki Goto
Original Assignee
Infectious Disease Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infectious Disease Res Inst filed Critical Infectious Disease Res Inst
Publication of BRPI0815565A2 publication Critical patent/BRPI0815565A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0815565-8A2A 2007-07-13 2008-07-11 Composições de esterol 24-c-metiltransferase de leishmania para a prevenção, tratamento e diagnóstico de leishmaniose. BRPI0815565A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94963707P 2007-07-13 2007-07-13
PCT/US2008/069843 WO2009012166A1 (en) 2007-07-13 2008-07-11 Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis

Publications (1)

Publication Number Publication Date
BRPI0815565A2 true BRPI0815565A2 (pt) 2015-02-18

Family

ID=39760688

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815565-8A2A BRPI0815565A2 (pt) 2007-07-13 2008-07-11 Composições de esterol 24-c-metiltransferase de leishmania para a prevenção, tratamento e diagnóstico de leishmaniose.

Country Status (6)

Country Link
US (1) US8916168B2 (pt)
EP (1) EP2170372A1 (pt)
CN (1) CN101743016B (pt)
BR (1) BRPI0815565A2 (pt)
EA (1) EA017958B1 (pt)
WO (1) WO2009012166A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710155A2 (pt) 2006-04-10 2011-08-23 Infectious Disease Res Inst Inc compostos e métodos para diagnóstico e tratamento de leishmaniose
US8425919B2 (en) * 2008-05-21 2013-04-23 Infectious Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
EP2291394B1 (en) 2008-07-03 2017-03-15 Infectious Disease Research Institute Fusion proteins and their use in the diagnosis and treatment of leishmaniasis
ES2352780B2 (es) * 2009-06-04 2011-09-15 Laboratorios Ovejero S.A. Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
EP2637687B1 (en) * 2010-11-08 2021-01-06 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US11318200B2 (en) * 2013-11-26 2022-05-03 Zoetis Services Llc Methods and compositions for induction of immune response
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR102748354B1 (ko) 2016-06-01 2024-12-31 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CA3173408A1 (en) 2020-12-23 2022-06-30 Access To Advanced Health Institute Solanesol vaccine adjuvants and methods of preparing same
CN114250206B (zh) * 2021-12-25 2024-03-19 苏州瀚源新酶生物科技有限公司 甲基转移酶突变体、重组载体、重组工程菌及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Also Published As

Publication number Publication date
EA201070140A1 (ru) 2010-08-30
EP2170372A1 (en) 2010-04-07
HK1144915A1 (en) 2011-03-18
CN101743016A (zh) 2010-06-16
US20090041798A1 (en) 2009-02-12
WO2009012166A1 (en) 2009-01-22
US8916168B2 (en) 2014-12-23
CN101743016B (zh) 2015-05-13
EA017958B1 (ru) 2013-04-30

Similar Documents

Publication Publication Date Title
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
PT2185157T (pt) Composições de dhea para o tratamento da menopausa
BRPI0812524A2 (pt) Amidohidrolases para a preparação de gêneros alimentícios ou estimulantes
BRPI0814157A2 (pt) Composição de catalisador e processos para a preparação e uma composição de catalisador e para desalquilação de etil-benzeno
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0815175A2 (pt) Dispositivo e procedimento para o diagnóstico ou para a preparação de diagnóstico e/ou para o monitoramento da terapia de doenças inflamatórias tal como artrite reumatóide
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
WO2008086025A3 (en) Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
BRPI0813352A2 (pt) Composições de fragmento de tecido para o tratamento de incontinência
IL194800A0 (en) Pre-mixed, ready-to-use pharmaceutical compositions
BRPI1013778A2 (pt) "equipamento para tratamento por imersão."
ZA201004622B (en) Method for increasing the therapeutic efficacy if curcuminoids and analogues
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI0916102A2 (pt) "método para a prevenção da hérnia paraestomal, método para preparar uma hérnia paraestomal e dispositivo para preparar ou reduzir a incidência da hérnia paraestomal"
BRPI0716985A2 (pt) Composição nutricional, uso da mesma, e, suplemento nutricional para o tratamento de pacientes que sofrem de alergias a alimentos
IL196136A (en) Its aminoindane or salt derivative, the pharmaceutical composition containing them and their uses
FI20065388A0 (fi) Betuliiniperäiset yhdisteet antimikrobisina aineina
NO20090724L (no) Benzylaminer, fremgangsmåte for fremstilling av slike, og anvendelse av dem som betennelseshemmende midler
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
BRPI0807903A2 (pt) Composições medicinais melhoradas compreendendo buprenorfina e nalmefeno.
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained